The national laboratory is committed to technological innovation and the local production of high-complexity medications.
Nuevo
Agregar La Derecha Diario en
Compartir:
The Argentine laboratory Gador inaugurated the first plant in the country dedicated to the development of treatments for rare genetic diseases, made possible by the growth and macroeconomic stability achieved by the Government of Javier Milei.
The company highlighted this project as a milestone within the national pharmaceutical industry, both for its scale and its technological level.
According to the company itself, the initiative represents “an unprecedented technological advancement for the local and regional pharmaceutical industry, positioning the country at the forefront of the development of cutting-edge medications.”
The plant.
This positioning reinforces Gador's intention to consolidate itself in a highly specialized segment within the global market.
The new facility is located in the Pilar Industrial Park and required an investment of USD 21.5 million. The complex is focused on the production of synthetic oligonucleotides, a high-precision technology that allows intervention on gene expression to regulate altered biological processes. This type of therapy is notable for its application in genetically derived diseases that present high complexity.
The site has a covered area of 1553 square meters and concentrates the stages of research, development, and production in one space.
Additionally, the infrastructure is complemented by an injectable plant equipped for filling vials and syringes, which expands the laboratory's operational capacity in the development of advanced treatments.
President Javier Milei.
The objectives of the new facility
One of the main objectives of this plant is the production of the first medication manufactured in the country for Skeletal Muscle Atrophy (SMA), a neurodegenerative genetic disease that currently has no cure and affects hundreds of people in Argentina.
According to details provided, this new therapeutic alternative will cost approximately 50% less than the innovative product available on the market.
The company emphasized the impact this innovation will have on the healthcare system. “The incorporation of this medication into the public health system represents a significant advancement in terms of access and equity, as it is a highly complex therapeutic alternative. This not only guarantees greater availability of the treatment for those who need it most, but also reinforces the capacity of the national healthcare system,” they specified in a statement.
The development of this plant took three years of work, including international validation processes, allowing Gador to project a reach beyond the local market.
In this regard, the company anticipated that about 80% of the production will be destined for export, focusing on regions such as Latin America, Europe, the United States, Asia, and the Middle East.
With this initiative, the laboratory not only expands its production capacity but also reinforces its positioning in a strategic segment of the global pharmaceutical industry, betting on innovation, accessibility, and international projection from Argentina.
